1The Vitamin K Cycle & Clotting Factor Activation
Vitamin K is the obligate co-factor for the microsomal enzyme gamma-glutamyl carboxylase. This enzyme mediates the post-translational carboxylation of specific glutamic acid residues into gamma-carboxyglutamic acid (Gla) domains on pro-coagulant clotting factors: Factor II (Prothrombin), Factor VII, Factor IX, and Factor X, alongside regulatory anticoagulant Protein C and Protein S.
These Gla residues function as high-affinity chelators of ionized calcium, inducing a conformational shift that enables clotting factor complexes to bind negatively charged phosphatidylserine surfaces on activated platelets. During this carboxylation reaction, reduced Vitamin K hydroquinone is oxidized to Vitamin K 2,3-epoxide. The enzyme Vitamin K Epoxide Reductase (VKOR) subsequently recycles the epoxide back to the hydroquinone state. Warfarin exerts its anticoagulant effect by non-competitively inhibiting VKOR, causing a rapid accumulation of non-functional, uncarboxylated clotting factor precursors (PIVKA).
2VKDB: Preventing Catastrophic Neonatal Hemorrhage
Vitamin K Deficiency Bleeding (VKDB), historically termed Hemorrhagic Disease of the Newborn, arises because human neonates are born with virtually absent hepatic stores. Contributing factors include minimal transplacental transfer of phylloquinone, a sterile gut microflora that does not synthesize menaquinones, and low maternal breast milk concentrations (1–3 mcg/L compared to 50 mcg/L in fortified formula).
| VKDB Category | Onset Window | Predominant Presentation | Prevention Regimen |
|---|---|---|---|
| Early VKDB | First 24 hours of life | Cephalohematoma, intrathoracic or intra-abdominal hemorrhage; linked to maternal enzyme-inducing drugs (phenytoin, rifampin). | Maternal oral K1 pre-delivery; immediate neonatal IM injection. |
| Classical VKDB | Days 2 to 7 of life | Gastrointestinal bleeding, umbilical bleeding, prolonged oozing after circumcision or venipuncture. | Routine birth dose (1.0 mg IM). |
| Late VKDB | Weeks 2 to 12 (up to 6 months) | 50–60% present as sudden catastrophic intracranial hemorrhage with high mortality and permanent neurodevelopmental sequelae. Exclusively breastfed infants. | Single IM birth shot prevents >99% of cases. Oral regimens are less reliable. |
- Birth weight >1500 g: 1.0 mg IM.
- Birth weight ≤1500 g: 0.5 mg IM.
3Warfarin Reversal: ACCP & ASH Guidelines
Management of supratherapeutic INR requires balancing the risk of life-threatening hemorrhage against rebound thromboembolism upon reversing chronic anticoagulation.
| Clinical Setting | INR Range | Recommended Action (ACCP Guidelines) |
|---|---|---|
| No Bleeding | 4.5 – 10.0 | Withhold 1–2 doses of warfarin; monitor INR closely. Routine Vitamin K is NOT recommended. |
| No Bleeding | > 10.0 | Withhold warfarin + administer 2.5 to 5.0 mg oral Vitamin K1. INR drops reliably within 24–48 hours. |
| Minor Bleeding | Any elevated INR | Withhold warfarin + administer 2.5 to 5.0 mg oral Vitamin K1. Recheck INR in 24 hours. |
| Major / Critical Bleed | Any elevated INR | 5 to 10 mg slow IV infusion over 20–30 mins + 4-factor Prothrombin Complex Concentrate (PCC) immediately. |
4Vitamin K1 (Phytonadione) vs. Vitamin K2 (Menaquinone)
| Property | Vitamin K1 (Phylloquinone / Phytonadione) | Vitamin K2 (Menaquinones: MK-4, MK-7) |
|---|---|---|
| Primary Source | Green leafy vegetables (spinach, kale, methi/fenugreek). | Bacterial fermentation (natto, curd, hard cheeses) and gut flora synthesis. |
| Primary Tissue Target | Hepatic: Clotting factor carboxylation (II, VII, IX, X). | Extra-hepatic: Bone (osteocalcin) and vasculature (Matrix Gla Protein). |
| Clinical Indications | VKDB prophylaxis, Warfarin/INR reversal, acute deficiency bleeding. | Bone mineral density maintenance and arterial calcification prevention. |
| Role in Reversal | Standard pharmacological agent worldwide. | Ineffective / NOT used for emergency anticoagulation reversal. |
5Vitamin K Response Test in Hepatic Disease
In cirrhotic patients with prolonged Prothrombin Time (PT), clinicians distinguish between fat malabsorption (common in biliary obstruction/cholestasis due to lack of bile salts) and primary hepatic parenchymal failure using the diagnostic Vitamin K Challenge:
- Administer 10 mg IV Vitamin K1 daily for 3 consecutive days.
- Improvement in PT/INR (>30% correction): Indicates pre-existing malabsorption with preserved hepatic biosynthetic machinery.
- Lack of Response: Confirms end-stage liver failure where functional hepatocyte mass is inadequate to synthesize clotting factor apoproteins regardless of Vitamin K repletion.